ABSTRACT
BACKGROUND: At the end of December 2019 it was described the first outbreak of atypical pneumonias in Wuhan, China, with the following detection of the agent of the genus coronavirus, today denominated SARS-CoV-2 and its disease COVID-19. CLINICAL CASE: A 41-year-old male patient affected by COVID-19 in the form of severe pneumonia (CORADS-6), who had no response to conventional drugs that only added comorbidity (QT prolongation), deserving non-invasive ventilatory strategy in the prone and conscious mode, combined with the administration of tocilizumab, presenting adequate clinical, blood gas, and tomographic evolution, currently without pulmonary sequelae. CONCLUSIONS: Many controlled clinical studies are still lacking in order to demonstrate the concrete utility of a specific drug and the current evidence leads to abandoning initially proposed schemes;however, some drugs may still have some utility in mild to moderate cases. © 2020 Comunicaciones Cientificas Mexicanas S.A. de C.V.. All rights reserved.